<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128713</url>
  </required_header>
  <id_info>
    <org_study_id>238</org_study_id>
    <secondary_id>U01HL072268</secondary_id>
    <secondary_id>U01HL072028</secondary_id>
    <secondary_id>U01HL072033</secondary_id>
    <secondary_id>U01HL072072</secondary_id>
    <secondary_id>U01HL072191</secondary_id>
    <secondary_id>U01HL072196</secondary_id>
    <secondary_id>U01HL072248</secondary_id>
    <secondary_id>U01HL072274</secondary_id>
    <secondary_id>U01HL072283</secondary_id>
    <secondary_id>U01HL072289</secondary_id>
    <secondary_id>U01HL072290</secondary_id>
    <secondary_id>U01HL072291</secondary_id>
    <secondary_id>U01HL072305</secondary_id>
    <secondary_id>U01HL072331</secondary_id>
    <secondary_id>U01HL072346</secondary_id>
    <secondary_id>U01HL072355</secondary_id>
    <secondary_id>U01HL072359</secondary_id>
    <nct_id>NCT00128713</nct_id>
  </id_info>
  <brief_title>Optimal Platelet Dose Strategy for Management of Thrombocytopenia</brief_title>
  <acronym>PLADO</acronym>
  <official_title>Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Transfusion Medicine/Hemostasis Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the three study arms of lower, medium, and
      higher dose platelet therapy with respect to the percentage of patients experiencing at least
      one episode of Grade 2 or higher bleeding as determined by the Platelet Dose Trial Bleeding
      Scale (Grade 2 bleeding corresponds to bleeding that is moderate, but not severe enough to
      warrant red blood cell transfusion).

      There are a number of secondary endpoints related to platelet transfusions, hemostasis, and
      other concerns. The four most important secondary endpoints will compare the three study arms
      with respect to the following outcomes: 1) platelet utilization rates (total number of
      platelets transfused x 10 ^11); 2) number of platelet transfusion events (frequency of
      transfusions); a transfusion event would be defined as each separate platelet transfusion
      issued by the study site's transfusion service; 3) highest category of bleeding during time
      of study (Platelet Dose Trial Bleeding Scale Grades less than or equal to 1, 2, 3, or 4 by
      arm); and 4) bleeding severity based on number of days with bleeding (total days of bleeding
      and bleeding/thrombocytopenic day), intensity of bleeding, and number of sites with bleeding
      (if such a severity score has been validated and published by the time the study is
      completed).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      It is important to identify the safest and most cost effective strategies for providing
      platelet support that will achieve effective disease management without depleting platelet
      supplies. Informative clinical data have been provided concerning the platelet transfusion
      trigger. In contrast, the optimal quantity of platelets to be used per transfusion remains a
      highly controversial subject. No prospective platelet transfusion studies have been performed
      in which patients are randomized to an assigned platelet dose throughout their period of
      thrombocytopenia.

      DESIGN NARRATIVE:

      After obtaining consent and verifying eligibility requirements, the patients will be
      randomized to one of three doses for prophylactic platelet transfusions (lower, medium, or
      higher dose). The dosage is based on the patient's body surface area (BSA). The dose targets
      are as follows: 1) the lower dose is 1.1 x 10^11/m²; 2) the medium dose is 2.2 x 10^11/m²;
      and 3) the higher dose is 4.4 x 10^11/m². A dose within 25% of this value in either direction
      is considered to be in the target range. For many adult patients, the typical dose of one
      unit of apheresis platelets would fall in the target range for the medium dose. All
      prophylactic transfusions provided while the patient is in the study will be given according
      to the randomized target dose range. Only blood bank staff, not clinical staff, will have
      access to the target dose range for each patient.

      The patient's morning platelet count will be taken every day. If this value is less than or
      equal to 10,000, a prophylactic platelet transfusion will be given. Otherwise, no
      prophylactic platelet transfusion will be given that day. Platelet transfusions may be given
      at any time, and at any dose, to treat active bleeding or in association with an invasive
      procedure. A hemostatic assessment will be carried out every day to identify any bleeding the
      patient may experience. This assessment involves a patient interview, physical assessment,
      and a chart review. Data on all transfusions (e.g., platelets and red blood cells), all
      transfusion-related events, all serious adverse events, and protocol deviations will also be
      recorded.

      Patients will participate in the study either until 30 days after the initial platelet
      transfusion, until they have not received a platelet transfusion for 10 days after the most
      recent platelet transfusion, or until hospital discharge (whichever comes first).

      Each of the three pairwise dose comparisons is of interest. Therefore, the primary and
      secondary endpoints will be analyzed using three separate pairwise comparisons, each at the
      0.017 significance level to adjust for multiple comparisons.

      This study has been approved by the National Heart, Lung, and Blood Institute
      (NHLBI)-appointed protocol review committee and data and safety monitoring board (DSMB), and
      each participating institution's institutional review board. An interim monitoring plan was
      developed by the protocol team and DSMB, and is described in the protocol. The study is being
      monitored in accordance with this plan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At Least One Day With Grade 2 or Higher Bleeding</measure>
    <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
    <description>Any Grade 2 (moderate) or higher grade bleeding, as determined by daily hemostatic assessment and documentation of any red blood cell transfusions to treat bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Utilization</measure>
    <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
    <description>Total number of platelets transfused, based on attempted dose, among subjects who have at least one platelet transfusion and no missing data on attempted doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Platelet Transfusion Episodes</measure>
    <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
    <description>Number of platelet transfusion episodes among subjects who have at least one platelet transfusion and no missing data on attempted doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Severity, if a Suitable Scale is Validated and Published by the Time the Trial Ends</measure>
    <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
    <description>No suitable scale was identified, so no analyses for this outcome were carried out</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Grade of Bleeding While on Study</measure>
    <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
    <description>Highest grade of bleeding during time on study using Platelet Dose Trial modification of World Health Organization Bleeding Scale. Grades 0-1 (no or minimal bleeding), 2 (moderate bleeding), 3 (bleeding generally requiring red cell transfusion), 4 (severe bleeding)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1351</enrollment>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lower Dose Prophylactic Platelets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium Dose Prophylactic Platelets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Higher Dose Prophylactic Platelets</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Medium Dose Prophylactic Platelet Transfusions</intervention_name>
    <description>2.2 x 10^11 platelets per m^2 BSA</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lower Dose Prophylactic Platelet Transfusions</intervention_name>
    <description>1.1 x 10^11 platelets per m^2 BSA</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Higher Dose Prophylactic Platelet Transfusions</intervention_name>
    <description>4.4 * 10^11 platelets per m^2 BSA</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has, or is expected to have, hypoproliferative thrombocytopenia, and is expected to
             have a platelet count of up to 10,000 ul for at least 5 days and be in the hospital
             for at least 5 days

          -  Weight is between 10 and 135 kilograms

          -  PT/INR, PTT, and fibrinogen assays that are measured within 72 hours before study
             entry are as follows:

               1. PT less than or equal to 1.3 times the upper limit of normal for the laboratory

               2. PTT less than or equal to 1.3 times the upper limit of normal for the laboratory

               3. Fibrinogen greater than or equal to 100 mg/dl

          -  Undergoing, or has completed, hematopoietic stem cell transplantation, for any
             diagnosis; OR has a diagnosis of acute or chronic leukemia, non-Hodgkins or Hodgkins
             lymphoma, myeloma, myelodysplasia, or non-hematologic malignancy and is undergoing, or
             has completed, chemotherapy

          -  During this hospitalization, the patient has not yet received any platelet
             transfusions related to the current or planned course of therapy (individual platelet
             transfusions given prior to the study and unrelated to thrombocytopenia will not
             exclude the patient)

        Exclusion Criteria:

          -  Evidence of greater than or equal to Grade 2 bleeding (as determined by the Platelet
             Dose Trial Bleeding Scale)

          -  Receiving antithrombotic drugs

          -  Will receive bedside leuko-reduced platelet transfusions

          -  Present, or history of, platelet transfusion refractoriness within 30 days prior to
             study entry

          -  Pre-enrollment lymphocytotoxic antibody screen (PRA) known to be greater than or equal
             to 20% based on prior data

          -  Present, or history of, acute promyelocytic leukemia (APML), immune thrombocytopenic
             purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or hemolytic-uremic syndrome
             (HUS)

          -  Will be transfused at platelet trigger of greater than 10,000 platelets/ul

          -  Recent history of major surgery (within 2 weeks of study entry)

          -  Currently taking, or participating in a study involving, platelet substitutes,
             platelet growth factors, or pharmacologic agents intended to enhance or decrease
             platelet hemostatic function

          -  Pregnant

          -  Previously enrolled in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan F. Assmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Research Institutes, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Brecher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James B. Bussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NY-Presbyterian Hosp/Weill Cornell Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U of Oklahoma Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John R. Hess</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher D. Hillyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara A. Konkle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cindy A. Leissinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith R. McCrae, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey McCullough, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janice G. McFarland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Center of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul M. Ness, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ellis Neufeld, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas L. Ortel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherrill J. Slichter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bloodworks (Puget Sound Blood Center)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald G. Strauss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darrell J. Triulzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Presbyterian and Shadyside Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospitals; Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Hospital and Clinics</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY-Presbyterian Hosp/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of Pennsylvania Health System; Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Presbyterian and Shadyside Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of Texas SW Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of Washington Medical Center/FHCRC; Children's Hospital and Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Alliance/St. Luke's Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Memorial Lutheran Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <results_first_submitted>January 30, 2009</results_first_submitted>
  <results_first_submitted_qc>May 29, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2009</results_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Transfusion</keyword>
  <keyword>Blood Platelets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lower Dose Platelets</title>
          <description>Lower Dose Prophylactic Platelets (1.1 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
        </group>
        <group group_id="P2">
          <title>Medium Dose Platelets</title>
          <description>Medium Dose Prophylactic Platelets (2.2 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
        </group>
        <group group_id="P3">
          <title>Higher Dose Platelets</title>
          <description>Higher Dose Prophylactic Platelets (4.4 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="453"/>
                <participants group_id="P2" count="449"/>
                <participants group_id="P3" count="449"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="453"/>
                <participants group_id="P2" count="449"/>
                <participants group_id="P3" count="449"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lower Dose Platelets</title>
          <description>Lower Dose Prophylactic Platelets (1.1 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
        </group>
        <group group_id="B2">
          <title>Medium Dose Platelets</title>
          <description>Medium Dose Prophylactic Platelets (2.2 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
        </group>
        <group group_id="B3">
          <title>Higher Dose Platelets</title>
          <description>Higher Dose Prophylactic Platelets (4.4 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="453"/>
            <count group_id="B2" value="449"/>
            <count group_id="B3" value="449"/>
            <count group_id="B4" value="1351"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="19.3"/>
                    <measurement group_id="B2" value="44.7" spread="19.3"/>
                    <measurement group_id="B3" value="45.5" spread="19.7"/>
                    <measurement group_id="B4" value="44.6" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 - 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 - 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=21 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="377"/>
                    <measurement group_id="B2" value="374"/>
                    <measurement group_id="B3" value="377"/>
                    <measurement group_id="B4" value="1128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="280"/>
                    <measurement group_id="B4" value="816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="374"/>
                    <measurement group_id="B3" value="378"/>
                    <measurement group_id="B4" value="1114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="433"/>
                    <measurement group_id="B2" value="425"/>
                    <measurement group_id="B3" value="423"/>
                    <measurement group_id="B4" value="1281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                    <measurement group_id="B2" value="449"/>
                    <measurement group_id="B3" value="449"/>
                    <measurement group_id="B4" value="1351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Regimen</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Autologous or syngeneic stem cell transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allogeneic stem cell transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="186"/>
                    <measurement group_id="B4" value="556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy for hematologic malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy for solid tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area</title>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.4"/>
                    <measurement group_id="B2" value="1.8" spread="0.4"/>
                    <measurement group_id="B3" value="1.8" spread="0.4"/>
                    <measurement group_id="B4" value="1.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.5" spread="21.4"/>
                    <measurement group_id="B2" value="164.0" spread="21.7"/>
                    <measurement group_id="B3" value="166.2" spread="19.3"/>
                    <measurement group_id="B4" value="165.2" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.4" spread="24.9"/>
                    <measurement group_id="B2" value="75.0" spread="26.3"/>
                    <measurement group_id="B3" value="76.0" spread="23.8"/>
                    <measurement group_id="B4" value="76.1" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>At Least One Day With Grade 2 or Higher Bleeding</title>
        <description>Any Grade 2 (moderate) or higher grade bleeding, as determined by daily hemostatic assessment and documentation of any red blood cell transfusions to treat bleeding</description>
        <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
        <population>These analyses were done on an intention-to-treat basis. That is, patients were counted in the treatment arm to which they were randomly assigned, even if they actually received transfusions that were not according to their assigned dosing strategy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lower Dose Platelets</title>
            <description>Lower Dose Prophylactic Platelets (1.1 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose Platelets</title>
            <description>Medium Dose Prophylactic Platelets (2.2 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose Platelets</title>
            <description>Higher Dose Prophylactic Platelets (4.4 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
        </group_list>
        <measure>
          <title>At Least One Day With Grade 2 or Higher Bleeding</title>
          <description>Any Grade 2 (moderate) or higher grade bleeding, as determined by daily hemostatic assessment and documentation of any red blood cell transfusions to treat bleeding</description>
          <population>These analyses were done on an intention-to-treat basis. That is, patients were counted in the treatment arm to which they were randomly assigned, even if they actually received transfusions that were not according to their assigned dosing strategy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="446"/>
                <count group_id="O2" value="435"/>
                <count group_id="O3" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                    <measurement group_id="O2" value="293"/>
                    <measurement group_id="O3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <p_value_desc>Three one-degree-of-freedom chi-square tests, each comparing a pair of treatment groups. These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <p_value_desc>Three one-degree-of-freedom chi-square tests, each comparing a pair of treatment groups. These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <p_value_desc>Three one-degree-of-freedom chi-square tests, each comparing a pair of treatment groups. These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Utilization</title>
        <description>Total number of platelets transfused, based on attempted dose, among subjects who have at least one platelet transfusion and no missing data on attempted doses.</description>
        <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
        <population>Subjects with missing information and those that did not receive at least one platelet transfusion were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lower Dose Platelets</title>
            <description>Lower Dose Prophylactic Platelets (1.1 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose Platelets</title>
            <description>Medium Dose Prophylactic Platelets (2.2 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose Platelets</title>
            <description>Higher Dose Prophylactic Platelets (4.4 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Utilization</title>
          <description>Total number of platelets transfused, based on attempted dose, among subjects who have at least one platelet transfusion and no missing data on attempted doses.</description>
          <population>Subjects with missing information and those that did not receive at least one platelet transfusion were excluded from the analysis.</population>
          <units>Number of platelets (x10^11)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="387"/>
                <count group_id="O3" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.96" lower_limit="0.67" upper_limit="196.35"/>
                    <measurement group_id="O2" value="12.49" lower_limit="1.06" upper_limit="487.33"/>
                    <measurement group_id="O3" value="22.43" lower_limit="2.49" upper_limit="363.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>All analyses are based on intention to treat. These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>All analyses are based on intention to treat. These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>All analyses are based on intention to treat. These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Platelet Transfusion Episodes</title>
        <description>Number of platelet transfusion episodes among subjects who have at least one platelet transfusion and no missing data on attempted doses.</description>
        <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
        <population>Subjects with missing information and those that did not receive at least one platelet transfusion were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lower Dose Platelets</title>
            <description>Lower Dose Prophylactic Platelets (1.1 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose Platelets</title>
            <description>Medium Dose Prophylactic Platelets (2.2 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose Platelets</title>
            <description>Higher Dose Prophylactic Platelets (4.4 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Platelet Transfusion Episodes</title>
          <description>Number of platelet transfusion episodes among subjects who have at least one platelet transfusion and no missing data on attempted doses.</description>
          <population>Subjects with missing information and those that did not receive at least one platelet transfusion were excluded from the analysis.</population>
          <units>Number of platelet transfusion episodes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="387"/>
                <count group_id="O3" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="58"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="111"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>All analyses were carried out using intention to treat. These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>All analyses were carried out using intention to treat. These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <p_value_desc>All analyses were carried out using intention to treat. These tests were carried out at the .017 significance level to adjust for the multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Severity, if a Suitable Scale is Validated and Published by the Time the Trial Ends</title>
        <description>No suitable scale was identified, so no analyses for this outcome were carried out</description>
        <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
        <population>Analysis not performed; no applicable bleeding severity scale validated and published by end of PLADO Study</population>
        <group_list>
          <group group_id="O1">
            <title>Lower Dose Platelets</title>
            <description>Lower Dose Prophylactic Platelets (1.1 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose Platelets</title>
            <description>Medium Dose Prophylactic Platelets (2.2 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose Platelets</title>
            <description>Higher Dose Prophylactic Platelets (4.4 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Severity, if a Suitable Scale is Validated and Published by the Time the Trial Ends</title>
          <description>No suitable scale was identified, so no analyses for this outcome were carried out</description>
          <population>Analysis not performed; no applicable bleeding severity scale validated and published by end of PLADO Study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Grade of Bleeding While on Study</title>
        <description>Highest grade of bleeding during time on study using Platelet Dose Trial modification of World Health Organization Bleeding Scale. Grades 0-1 (no or minimal bleeding), 2 (moderate bleeding), 3 (bleeding generally requiring red cell transfusion), 4 (severe bleeding)</description>
        <time_frame>From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first)</time_frame>
        <population>The analysis was done as intention to treat. Subjects for which highest grade of bleeding could not be determined (non-evaluable) were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Lower Dose Platelets</title>
            <description>Lower Dose Prophylactic Platelets (1.1 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose Platelets</title>
            <description>Medium Dose Prophylactic Platelets (2.2 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose Platelets</title>
            <description>Higher Dose Prophylactic Platelets (4.4 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Grade of Bleeding While on Study</title>
          <description>Highest grade of bleeding during time on study using Platelet Dose Trial modification of World Health Organization Bleeding Scale. Grades 0-1 (no or minimal bleeding), 2 (moderate bleeding), 3 (bleeding generally requiring red cell transfusion), 4 (severe bleeding)</description>
          <population>The analysis was done as intention to treat. Subjects for which highest grade of bleeding could not be determined (non-evaluable) were excluded.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="423"/>
                <count group_id="O3" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0 or 1 (no bleeding or minimal bleeding)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (moderate bleeding)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="244"/>
                    <measurement group_id="O3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (bleeding generally requiring RBC's)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (severe bleeding)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <p_value_desc>Each pair of treatment arms was compared using an exact version of the Mantel-Haenszel test for trend.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>These tests will be carried out at the .017 significance level to adjust for the multiple comparisons</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <p_value_desc>Each pair of treatment arms was compared using an exact version of the Mantel-Haenszel test for trend.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>These tests will be carried out at the .017 significance level to adjust for the multiple comparisons</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>Each pair of treatment arms was compared using an exact version of the Mantel-Haenszel test for trend.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>These tests will be carried out at the .017 significance level to adjust for the multiple comparisons</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For serious adverse events (SAE): from randomization until the subject ends the study. For adverse events (AE) other than SAEs: during and within the 4 hours following each transfusion.</time_frame>
      <desc>Subjects ended the study 10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or at hospital discharge or death, whichever occurs first.
Throughout their time on study, subjects were hospitalized. Assessment for AE and SAE was through review of medical records and daily assessment of subject.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lower Dose Platelets</title>
          <description>Lower Dose Prophylactic Platelets (1.1 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
        </group>
        <group group_id="E2">
          <title>Medium Dose Platelets</title>
          <description>Medium Dose Prophylactic Platelets (2.2 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
        </group>
        <group group_id="E3">
          <title>Higher Dose Platelets</title>
          <description>Higher Dose Prophylactic Platelets (4.4 x 10^11 per m^2 Body Surface Area per transfusion, +/- 25%)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="453"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="449"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypovolemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Heart Block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypotension and Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic Ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Perforated Appendix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rectal Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema and Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Chest Pain - Probably Due To Chemotherapy Toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Failed Engraftment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fever with Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fever, Rigors and Shortness of Breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hemodynamic Instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypotension and Possible Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypotension and Hypoxemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Multisystem Organ Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Respiratory Distress and Multiorgan Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Respiratory Distress and Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Sepsis and Multiorgan Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Septic Shock and Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-Occlusive Disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="453"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="449"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Graft-Versus-Host Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Possible Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Possible Toxoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="453"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="449"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Burkitt's Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Relapse of Acute Myelogenous Leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Intracranial Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Obtunded Level of Consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Subarachnoid Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Subdural Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolar Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hemoptysis and Respiratory Distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Intubation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Pulmonary Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="453"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="449"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Transfusion Related Acute Lung Injury vs Fluid Overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic Epidermal Necrolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="453"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="453"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="449"/>
                <counts group_id="E3" subjects_affected="203" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="453"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="453"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="449"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" events="91" subjects_affected="43" subjects_at_risk="453"/>
                <counts group_id="E2" events="86" subjects_affected="41" subjects_at_risk="449"/>
                <counts group_id="E3" events="54" subjects_affected="35" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="81" subjects_affected="39" subjects_at_risk="453"/>
                <counts group_id="E2" events="61" subjects_affected="34" subjects_at_risk="449"/>
                <counts group_id="E3" events="75" subjects_affected="46" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="52" subjects_affected="32" subjects_at_risk="453"/>
                <counts group_id="E2" events="28" subjects_affected="23" subjects_at_risk="449"/>
                <counts group_id="E3" events="36" subjects_affected="25" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Rigors, chills</sub_title>
                <counts group_id="E1" events="55" subjects_affected="37" subjects_at_risk="453"/>
                <counts group_id="E2" events="55" subjects_affected="42" subjects_at_risk="449"/>
                <counts group_id="E3" events="72" subjects_affected="49" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="425" subjects_affected="153" subjects_at_risk="453"/>
                <counts group_id="E2" events="333" subjects_affected="133" subjects_at_risk="449"/>
                <counts group_id="E3" events="358" subjects_affected="143" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction/Hypersensitivity</sub_title>
                <counts group_id="E1" events="50" subjects_affected="37" subjects_at_risk="453"/>
                <counts group_id="E2" events="60" subjects_affected="46" subjects_at_risk="449"/>
                <counts group_id="E3" events="82" subjects_affected="55" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="453"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="449"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="453"/>
                <counts group_id="E2" events="30" subjects_affected="20" subjects_at_risk="449"/>
                <counts group_id="E3" events="22" subjects_affected="18" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="453"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="449"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="453"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="453"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="449"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="449"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Assmann, PhD</name_or_title>
      <organization>New England Research Institutes</organization>
      <phone>617-923-7747 ext 548</phone>
      <email>sassmann@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

